News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Depomed, Inc. (DEPO) Reports Second Quarter 2014 Financial Results


8/7/2014 8:46:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aug. 6, 2014
/PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2014.

Second Quarter 2014 Summary

  • Total product sales of $28.2 million increased 100% compared to $14.1 million for the second quarter of 2013, and increased 31% from $21.5 million for the first quarter of 2014
    • Gralise® (gabapentin) product sales of $15.1 million increased 39% from $10.9 million for the first quarter of 2014 and 76% compared to $8.6 million for the second quarter of 2013
    • Zipsor® (diclofenac potassium) product sales of $6.8 million increased 28% from $5.3 million for the first quarter of 2014 and 21% compared to $5.6 million for the second quarter of 2013
    • Cambia® (diclofenac potassium for oral solution) product sales of $5.0 million increased 9% from $4.6 million for the first quarter of 2014
    • Lazanda® (fentanyl) Nasal Spray product sales of $1.4 million increased 100% from $0.7 million for the first quarter of 2014
  • Gralise added to tier 2 formulary at Catamaran, the 3rd largest PBM. Gralise is now tier 2 with the top 3 PBMs
  • Received a total of $15 million in milestone payments from Mallinckrodt during the quarter, which included a $10 million FDA approval milestone for Xartemis XR® (recognized as revenue in the first quarter of 2014) and a $5 million milestone upon FDA acceptance of the NDA filing for MNK-155 (recognized as revenue in the second quarter of 2014)
  • Generated second quarter 2014 GAAP net income of $12.7 million or $0.21 per diluted share
  • Generated second quarter 2014 non-GAAP adjusted earnings of $0.3 million or $0.01 per diluted share
  • $223.7 million of cash and marketable securities and no debt outstanding as of June 30, 2014, an increase of $10.6 million for the quarter
  • Completed bench trial in ANDA litigation related to Gralise with a ruling expected in short order
  • Srinivas G. Rao, MD, PhD, joined Depomed in July as Chief Medical Officer and announced that R. Scott Shively will join the company as Chief Commercial Officer in September

"Gralise and our recent acquisitions, CAMBIA and Lazanda, led the way to a strong quarter, doubling our net product sales over the same period last year.  All four of our products showed prescription growth in Q2 compared to Q1 2014," said Jim Schoeneck, President and Chief Executive Officer of Depomed.  "We believe the growth of our product revenues in Q2 and the integration of new products into our commercial organization demonstrate our ability to build a growth-oriented specialty pharmaceutical company focused on pain and central nervous system disorders. We are also thrilled to add Srini and Scott to our leadership team, increasing our depth and expertise in the pain and CNS markets.  For the remainder of 2014, we are focused on growing product revenues, acquiring additional assets that will enhance our product portfolio and managing expenses to continue to operate at positive cash flow."

Accounting Treatment for the Sale of Type 2 Diabetes Royalty and Milestone Interests to PDL

In October 2013, Depomed sold interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL Biopharma, Inc. (PDL) for $240.5 million. As a result of ongoing supply order obligations with respect to the underlying royalties, Depomed is accounting for this transaction under the debt accounting method. Although the royalty and milestone payments were sold to PDL, debt accounting requires the Company to continue to recognize the underlying royalties and milestones as revenue and record the proceeds of $240.5 million as a liability. As royalties and milestones are recognized under this arrangement, the liability is reduced and an implied non-cash interest expense is recognized.

During the three and six months ended June 30, 2014, Depomed recognized $33.3 million and $76.1 million, respectively, of non-cash revenues, $4.9 million and $10.3 million, respectively, in non-cash interest expense and $8.3 million and  $20.1 million, respectively, in non-cash tax expense related to this arrangement.

Second Quarter 2014 Financial Results

Total revenues for the second quarter of 2014 increased to $67.7 million from $30.0 million for the second quarter of 2013. A summary of total revenues for the first quarter of 2014 as compared to the corresponding prior period is as follows:














Three Months Ended 


Six Months Ended 


June 30,


June 30,


2014


2013


2014


2013


(Unaudited)


(Unaudited)


(Unaudited)


(Unaudited)

Product sales:












Gralise

$

15,111


$

8,554


$

25,970


$

14,643

Zipsor


6,822



5,552



12,165



8,592

CAMBIA (1)


4,958



-



9,582



-

Lazanda (1)


1,354



-



2,034



-

         Total product sales 


28,245



14,106



49,751



23,235













Royalties:












Glumetza US

$

-


$

14,193


$

-


$

27,481

Other


430



904



925



1,697

            Total royalty revenue


430



15,097



925



29,178













License and other revenue:












Mallinckrodt

$

5,000


$

-


$

15,000


$

-

Janssen


-



-



-



2,204

Glumetza


760



760



1,520



1,520

Other


-



-



1,000



-

         Total license and other revenue


5,760



760



17,520



3,724













Non-cash PDL royalty revenue

$

33,297


$

-


$

76,081


$

-













Total revenues (GAAP Basis)

$

67,732


$

29,963


$

144,277


$

56,137


(1)   Depomed acquired Lazanda in July 2013 and CAMBIA in December 2013.

Selling, general and administrative expense was $32.6 million for the second quarter of 2014 as compared to $25.4 million for the second quarter of 2013. The increase in 2014 is primarily due to increased sales and marketing expenses associated with the Cambia and Lazanda® product acquisitions which occurred in the second half of 2013 and increased legal expense related to ongoing patent infringement litigation.

Research and development expense was $1.4 million for the second quarter of 2014 as compared to $1.4 million for the second quarter of 2013.

GAAP net income for the second quarter of 2014 was $12.7 million, or $0.21 per diluted share, compared to GAAP net income of $0.5 million, or $0.01 per diluted share for the second quarter of 2013.  The increase in GAAP net income resulted primarily from increased product sales and the recognition of non-cash revenue relating to the royalties sold to PDL as described above under the caption "Accounting Treatment for the Sale of Type 2 Diabetes Royalties and Milestones to PDL."

Cash and marketable securities were $223.7 million as of June 30, 2014 as compared to $213.1 million as of March 31, 2014.

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES